found Documents: 808

Announcements & Press Releases, Group, Press Releases | 16 Mar 2017

Grant of Awards under Long Term Incentive Plan

1 item

Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a

Download Press Release (PDF)

Announcements & Press Releases, Group | 13 Mar 2017

Publication of Form 20-F for the Year Ended December 31, 2016

1 item

London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww

View Form 20-F (PDF)

Announcements & Press Releases, Group | 13 Mar 2017

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

1 item

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%

View Full Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Mar 2017

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

1 item

Press Release London: Friday, March 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) presented data from the ongoing Phase Ib/II clinical trial of sulfatinib in patients with advanced neuroendocrine tumors (“NET”) at

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Mar 2017

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

1 item

– Trial met all primary and secondary endpoints – – Safety as expected – – Progressing to China NDA submission mid-2017 – – Full data to be reported at an upcoming scientific meeting in mid-2017 – London: Friday, March 3, 2017: Hu

Grant of Awards under Long Term Incentive Plan

Publication of Form 20-F for the Year Ended December 31, 2016

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Chi-Med to Announce 2016 Final Results

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

Total Voting Rights

Blocklisting Six Monthly Return

Director’s Share Dealing

Director’s Share Dealing

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

Exercise of Share Options by a Person Discharging Managerial Responsibilities

Total Voting Rights

Director’s Share Dealing

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)

Chi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting

Director's Share Dealing

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Director's Share Dealing

Director's Share Dealing

Change of Non-executive Directors

Chi-Med Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs

Chi-Med and AstraZeneca Amend Co-development Agreement to Accelerate Savolitinib Global Development Program

Chi-Med to Announce 2016 Half-Year Financial Results

Blocklisting Six Monthly Return

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Block Admission

Total Voting Rights

Chi-Med Completes Enrollment of 416 Patients in Pivotal Phase III FRESCO Trial with Fruquintinib in Colorectal Cancer

Chi-Med to Participate in Two Healthcare Investor Conferences in May

Total Voting Rights

Results of Annual General Meeting

Hutchison China MediTech Limited Announces Exercise of Overallotment Option

Chi-Med initiates first-in-human clinical trial of novel PI3K inhibitor HMPL-689

Total Voting Rights

Director's Shareholding

Holding(s) in Company

Closing of U.S. Public Offering of ADSs Raising Approximately US$101 Million on the Nasdaq Stock Market

Director's Shareholding

Chi-Med initiates sulfatinib Phase III registration study in pancreatic neuroendocrine tumor patients